Prevention and treatment of breast cancer using melatonin

Melatonin in the Promotion of Health: Second Edition

Volumn , Issue , 2011, Pages 271-286

  Davis, Vicki L ^a   Dodda, Balasunder R ^a   Witt Enderby, Paula A ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84894269980     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (134)

1. Jemal, A, Siegel, R, Ward, E, et al. 2008. Cancer statistics, 2008. CA Cancer J Clin 58: 71-96
2. Tsao, AS, Kim, ES, Hong, WK. 2004. Chemoprevention of cancer. CA Cancer J Clin 54: 150-180
3. Fisher, B, Costantino, JP, Wickerham, DL, et al. 1998. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388
4. Wolmark, N, Dunn, BK. 2001. The role of tamoxifen in breast cancer prevention: Issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann N Y Acad Sci 949: 99-108
5. Zhdanova, IV, Wurtman, RJ, Balcioglu, A, Kartashov, AI Lynch, HJ. 1998. Endogenous melatonin levels and the fate of exogenous melatonin: Age effects. J Gerontol A Biol Sci Med Sci 53: B293-B298
6. Bartsch, C, Bartsch, H, Karasek, M. 2002. Melatonin in clinical oncology. Neuro Endocrinol Lett 23 Suppl 1: 30-38
7. Zawilska, JB, Skene, DJ, Arendt, J. 2009. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep 61: 383-410
8. Leger, D, Laudon, M, Zisapel, N. 2004. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 116: 91-95
9. Karasek, M, Winczyk, K. 2006. Melatonin in humans. J Physiol Pharmacol 57 Suppl 5: 19-39
10. Cohen, M, Lippman, M, Chabner, B. 1978. Role of pineal gland in aetiology and treatment of breast cancer. Lancet 2: 814-816
11. Kos-Kudla, B, Ostrowska, Z, Marek, B, et al. 2002. Circadian rhythm of melatonin in postmenopausal asthmatic women with hormone replacement therapy. Neuro Endocrinol Lett 23: 243-248
12. Sanchez-Barcelo, EJ, Cos, S, Mediavilla, D, Martinez-Campa, C, Gonzalez, A, Alonso-Gonzalez, C. 2005. Melatonin-estrogen interactions in breast cancer. J Pineal Res 38: 217-222
13. Tamarkin, L, Danforth, D, Lichter, A, et al. 1982. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 216: 1003-1005
14. Schernhammer, ES, Hankinson, SE. 2009. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. Cancer Epidemiol Biomarkers Prev 18: 74-79
15. Stevens, RG. 1987. Electric power use and breast cancer: A hypothesis. Am J Epidemiology 125.4: 556-561
16. Davis, S, Mirick, DK, Stevens, RG. 2001. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93: 1557-1562
17. Davis, S, Mirick, DK. 2006. Circadian disruption, shift work and the risk of cancer: A summary of the evidence and studies in Seattle. Cancer Causes Control 17: 539-545
18. Coleman, MP, Reiter, RJ. 1992. Breast cancer, blindness and melatonin. Eur J Cancer 28: 501-503
19. Grant, SG, Melan, MA, Latimer, JJ, Witt-Enderby, PA. 2009. Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 11: e5
20. Burch, JB, Walling, M, Rush, A, et al. 2007. Melatonin and estrogen in breast cyst fluids. Breast Cancer Res Treat 103: 331-341
21. Bartsch, C, Kvetnoy, I, Kvetnaia, T, et al. 1997. Nocturnal urinary 6-sulfatoxymelatonin and proliferating cell nuclear antigen-immunopositive tumor cells show strong positive correlations in patients with gastrointestinal and lung cancer. J Pineal Res 23: 90-96
22. Maestroni, GJ, Conti, A. 1996. Melatonin in human breast cancer tissue: Association with nuclear grade and estrogen receptor status. Lab Invest 75: 557-561
23. Blask, DE. 1997. The melatonin rhythm in cancer patients, Washington, D.C., American Psychiatric Press
24. Panzer, A, Viljoen, M. 1997. The validity of melatonin as an oncostatic agent. J Pineal Res 22: 184-202
25. Mills, E, Wu, P, Seely, D, Guyatt, G. 2005. Melatonin in the treatment of cancer: A systematic review of randomized controlled trials and meta-analysis. J Pineal Res 39: 360-366
26. Lissoni, P, Di Fede, G, Battista, A, et al. 2009. A phase II study of anastrozole plus the pineal anticancer hormone melatonin in the metastatic breast cancer women with poor clinical status. Cancer Ther 7: 302-304
27. Vesnushkin, GM, Plotnikova, NA, Semenchenko, AI, Anisimov, VN. 2006. Dose-dependent inhibitory effect of melatonin on carcinogenesis induced by benzo[a]pyrene in mice. J Exp Clin Cancer Res 25: 507-513
28. Viii, B. 2006. Health Risks from Exposure to Low Levels of Ionizing Radiation, National Academies Press, Washington, DC
29. Rogelsperger, O, Ekmekcioglu, C, Jager, W, et al. 2009. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res 46: 422-432
30. Cos, S, Gonzalez, A, Martinez-Campa, C, Mediavilla, MD, Alonso-Gonzalez, C Sanchez-Barcelo, EJ. 2006. Estrogen-signaling pathway: A link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 30: 118-128
31. Treilleux, Peloux, N, Brown, M Sergeant, A. 1997. Human estrogen receptor (ER) gene promoter-P1: Estradiol-independent activity and estradiol inducibility in ER+ and ER-cells. Mol Endocrinol 11: 1319-1331
32. Cunat, S, Hoffmann, P, Pujol, P. 2004. Estrogens and epithelial ovarian cancer. Gynecol Oncol 94: 25-32
33. Naderi, A, Teschendorff, AE, Beigel, J, et al. 2007. BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res 67: 6725-6736
34. Kothari, LS. 1987. Influence of chronic melatonin on 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors in female Holtzman rats exposed to continuous light. Oncology 44: 64-66
35. Anisimov, VN. 2006. Light pollution, reproductive function and cancer risk. Neuro Endocrinol Lett 27: 35-52
36. Cos, S Sanchez-Barcelo, EJ. 2000. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 15: 637-647
37. Shah, PN, Mhatre, MC, Kothari, LS. 1984. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res 44: 3403-3407
38. Tamarkin, L, Cohen, M, Roselle, D, Reichert, C, Lippman, M, Chabner, B. 1981. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 41: 4432-4436
39. Graham, C, Cook, Mr, Gerkovich, MM, Sastre, A. 2001. Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ Health Perspect 109: 501-507
40. Blask, DE, Brainard, GC, Dauchy, RT, et al. 2005. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 65: 11174-11184
41. Subramanian, A, Kothari, L. 1991. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1, 2-benzanthracene (DMBA-)induced rat mammary gland carcinogenesis. Anticancer Drugs 2: 297-303
42. Anisimov, VN, Alimova, IN, Baturin, DA, et al. 2003. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer 103: 300-305
43. Baturin, DA, Alimova, IN, Anisimov, VN, et al. 2001. The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression. Neuro Endocrinol Lett 22: 441-447
44. Mediavilla, MD, Guezmez, A, Ramos, S, Kothari, L, Garijo, F, Sanchez Barcelo, EJ. 1997. Effects of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene. J Pineal Res 22: 86-94
45. Rao, GN, Ney, E, Herbert, RA. 2000. Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res Treat 64: 287-296
46. Witt-Enderby, PA, Radio, NM, Doctor, JS, Davis, VL. 2006. Therapeutic treatments potentially mediated by melatonin receptors: Potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 41: 297-305
47. Blask, DE, Pelletier, DB, Hill, SM, et al. 1991. Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: Potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117: 526-532
48. Lenoir, V, De Jonage-Canonico, MB, Perrin, MH, Martin, A, Scholler, R, Kerdelhue, B. 2005. Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res 7: R470-476
49. Cos, S, Mediavilla, D, Martinez-Campa, C, Gonzalez, A, Alonso-Gonzalez, C, Sanchez-Barcelo, EJ. 2006. Exposure to light-at-night increases the growth of DMBA-induced mammary adenocarcinomas in rats. Cancer Lett 235: 266-271
50. Kothari, A, Borges, A, Kothari, L. 1995. Chemoprevention by melatonin and combined melatonin-tamoxifen therapy of second generation nitroso-methylurea-induced mammary tumours in rats. Eur J Cancer Prev 4: 497-500
51. Kubatka, P, Bojkova, B, K, Mc-K, et al. 2001. Effects of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea and by 7,12-dimethylbenz(a)anthracene, respectively, in female Sprague-Dawley rats. Folia Biol (Praha) 47: 5-10
52. Collins, A, Yuan, L, Kiefer, TL, Cheng, Q, Lai, L, Hill, SM. 2003. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice. Cancer Lett 189: 49-57
53. Recio, J, Cardinali, DP, Sanchez-Barcelo, EJ. 1994. 2-[125I]iodomelatonin binding sites in murine mammary tissue. Biol Signals 3: 85-90
54. Cos, S, Fernandez, R, Guezmes, A, Sanchez-Barcelo, EJ. 1998. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58: 4383-4390
55. Hill, SM, Frasch, T, Xiang, S, Yuan, L, Duplessis, T, Mao, L. 2009. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 8: 337-346
56. Danielczyk, K, Dziegiel, P. 2009. The expression of MT1 melatonin receptor and Ki-67 antigen in melanoma malignum. Anticancer Res 29: 3887-3895
57. Martinez-Campa, C, Alonso-Gonzalez, C, Mediavilla, MD, et al. 2006. Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J Pineal Res 40: 291-296
58. Reiter, RJ, Paredes, SD, Manchester, LC, Tan, DX. 2009. Reducing oxidative/nitrosative stress: A newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 44: 175-200
59. Luchetti, F, Betti, M, Canonico, B, et al. 2009. ERK MAPK activation mediates the antiapoptotic signaling of melatonin in UVB-stressed U937 cells. Free Radic Biol Med 46: 339-351
60. Acuna-Castroviejo, D, Escames, G, Rodriguez, MI, Lopez, LC. 2007. Melatonin role in the mitochondrial function. Front Biosci 12: 947-963
61. Reiter, RJ, Tan, D, Kim, SJ, et al. 1999. Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. Mech Ageing Dev 110: 157-173
62. Morioka, N, Okatani, Y, Wakatsuki, A. 1999. Melatonin protects against age-related DNA damage in the brains of female senescence-accelerated mice. J Pineal Res 27: 202-209
63. Anisimov, VN, Alimova, IN, Baturin, DA, et al. 2003. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. Exp Gerontol 38: 449-461
64. Vijayalaxmi, Reiter, RJ, Tan, DX, Herman, TS, Thomas, CR, Jr. 2004. Melatonin as a radioprotective agent: A review. Int J Radiat Oncol Biol Phys 59: 639-653
65. Sanchez-Barcelo, EJ, Cos, S, Fernandez, R, Mediavilla, MD. 2003. Melatonin and mammary cancer: A short review. Endocr Relat Cancer 10: 153-159
66. Cos, S, Recio, J, Sanchez-Barcelo, EJ. 1996. Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci 58: 811-816
67. Jones, MP, Melan, MA, Witt-Enderby, PA. 2000. Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner. Cancer Lett 151: 133-143
68. Girgert, R, Hanf, V, Emons, G, Grundker, C. 2009. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 47: 23-31
69. Dai, J, Inscho, EW, Yuan, L, Hill, SM. 2002. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. J Pineal Res 32: 112-119
70. Gonzalez, A, Cos, S, Martinez-Campa, C, et al. 2008. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 45: 86-92
71. Del Rio, B, Garcia Pedrero, JM, Martinez-Campa, C, Zuazua, P, Lazo, PS, Ramos, S. 2004. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 279: 38294-38302
72. Kiefer, T, Ram, PT, Yuan, L, Hill, SM. 2002. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 71: 37-45
73. Rato, AG, Pedrero, JG, Martinez, MA, Del Rio, B, Lazo, PS, Ramos, S. 1999. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13: 857-868
74. Martinez-Campa, C, Gonzalez, A, Mediavilla, MD, et al. 2009. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 101: 1613-1619
75. Aust, S, Jaeger, W, Klimpfinger, M, et al. 2005. Biotransformation of melatonin in human breast cancer cell lines: Role of sulfotransferase 1A1. J Pineal Res 39: 276-282
76. Kothari, A, Borges, A, Ingle, A, Kothari, L. 1997. Combination of melatonin and tamoxifen as a chemoprophylaxis against N-nitroso-N-methylurea-induced rat mammary tumors. Cancer Lett 111: 59-66
77. Hill, SM, Teplitzky, S, Ram, PT, et al. 1999. Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer. Adv Exp Med Biol 460: 345-362
78. Cos, S, Gonzalez, A, Guezmes, A, et al. 2006. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118: 274-278
79. Melancon, K, Cheng, Q, Kiefer, TL, et al. 2005. Regression of NMU-induced mammary tumors with the combination of melatonin and 9-cis-retinoic acid. Cancer Lett 227: 39-48
80. Moselhy, SS, Al Mslmani, MA. 2008. Chemopreventive effect of lycopene alone or with melatonin against the genesis of oxidative stress and mammary tumors induced by 7,12 dimethyl(a)benzanthracene in sprague dawely female rats. Mol Cell Biochem 319: 175-180
81. Russo, J, Balogh, GA, Heulings, R, et al. 2006. Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev 15: 306-342
82. Luttrell, LM. 2002. Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors. Can J Physiol Pharmacol 80: 375-382
83. Satomura, K, Tobiume, S, Tokuyama, R, et al. 2007. Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. J Pineal Res 42: 231-239
84. Sanchez-Hidalgo, M, Lu, Z, Tan, DX, Maldonado, MD, Reiter, RJ, Gregerman, RI. 2007. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: Implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol 292: R2208-2215
85. Schuster, C, Williams, LM, Morris, A, Morgan, PJ, Barrett, P. 2005. The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol 17: 170-178
86. Johnston, JD, Klosen, P, Barrett, P, Hazlerigg, DG. 2006. Regulation of MT melatonin receptor expression in the foetal rat pituitary. J Neuroendocrinol 18: 50-56
87. Radio, NM, Doctor, JS, Witt-Enderby, PA. 2006. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 40: 332-342
88. Sainz, RM, Mayo, JC, Tan, DX, Leon, J, Manchester, L, Reiter, RJ. 2005. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63: 29-43
89. Bellon, A, Ortiz-Lopez, L, Ramirez-Rodriguez, G, Anton-Tay, F, Benitez-King, G. 2007. Melatonin induces neuritogenesis at early stages in N1E-115 cells through actin rearrangements via activation of protein kinase C and Rho-associated kinase. J Pineal Res 42: 214-221
90. Moriya, T, Horie, N, Mitome, M, Shinohara, K. 2007. Melatonin influences the proliferative and differentiative activity of neural stem cells. J Pineal Res 42: 411-418.68. Jones, MP, Melan, MA, Witt-Enderby, PA. 2000. Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner. Cancer Lett 151: 133-143
91. Jones, MP, Melan, MA, Witt-Enderby, PA. 2000. Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner. Cancer Lett 151: 133-143
92. Girgert, R, Hanf, V, Emons, G, Grundker, C. 2009. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 47: 23-31
93. Dai, J, Inscho, EW, Yuan, L, Hill, SM. 2002. Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells. J Pineal Res 32: 112-119
94. Gonzalez, A, Cos, S, Martinez-Campa, C, et al. 2008. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 45: 86-92
95. Del Rio, B, Garcia Pedrero, JM, Martinez-Campa, C, Zuazua, P, Lazo, PS, Ramos, S. 2004. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 279: 38294-38302
96. Kiefer, T, Ram, PT, Yuan, L, Hill, SM. 2002. Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells. Breast Cancer Res Treat 71: 37-45
97. Rato, AG, Pedrero, JG, Martinez, MA, Del Rio, B, Lazo, PS, Ramos, S. 1999. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13: 857-868
98. Martinez-Campa, C, Gonzalez, A, Mediavilla, MD, et al. 2009. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 101: 1613-1619
99. Aust, S, Jaeger, W, Klimpfinger, M, et al. 2005. Biotransformation of melatonin in human breast cancer cell lines: Role of sulfotransferase 1A1. J Pineal Res 39: 276-282
100. Kothari, A, Borges, A, Ingle, A, Kothari, L. 1997. Combination of melatonin and tamoxifen as a chemoprophylaxis against N-nitroso-N-methylurea-induced rat mammary tumors. Cancer Lett 111: 59-66
101. Hill, SM, Teplitzky, S, Ram, PT, et al. 1999. Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer. Adv Exp Med Biol 460: 345-362
102. Cos, S, Gonzalez, A, Guezmes, A, et al. 2006. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118: 274-278
103. Melancon, K, Cheng, Q, Kiefer, TL, et al. 2005. Regression of NMU-induced mammary tumors with the combination of melatonin and 9-cis-retinoic acid. Cancer Lett 227: 39-48
104. Moselhy, SS, Al Mslmani, MA. 2008. Chemopreventive effect of lycopene alone or with melatonin against the genesis of oxidative stress and mammary tumors induced by 7,12 dimethyl(a)benzanthracene in sprague dawely female rats. Mol Cell Biochem 319: 175-180
105. Russo, J, Balogh, GA, Heulings, R, et al. 2006. Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev 15: 306-342
106. Luttrell, LM. 2002. Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors. Can J Physiol Pharmacol 80: 375-382
107. Satomura, K, Tobiume, S, Tokuyama, R, et al. 2007. Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. J Pineal Res 42: 231-239
108. Sanchez-Hidalgo, M, Lu, Z, Tan, DX, Maldonado, MD, Reiter, RJ, Gregerman, RI. 2007. Melatonin inhibits fatty acid-induced triglyceride accumulation in ROS17/2.8 cells: Implications for osteoblast differentiation and osteoporosis. Am J Physiol Regul Integr Comp Physiol 292: R2208-2215
109. Schuster, C, Williams, LM, Morris, A, Morgan, PJ, Barrett, P. 2005. The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol 17: 170-178
110. Johnston, JD, Klosen, P, Barrett, P, Hazlerigg, DG. 2006. Regulation of MT melatonin receptor expression in the foetal rat pituitary. J Neuroendocrinol 18: 50-56
111. Radio, NM, Doctor, JS, Witt-Enderby, PA. 2006. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 40: 332-342
112. Sainz, RM, Mayo, JC, Tan, DX, Leon, J, Manchester, L, Reiter, RJ. 2005. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 63: 29-43
113. Bellon, A, Ortiz-Lopez, L, Ramirez-Rodriguez, G, Anton-Tay, F, Benitez-King, G. 2007. Melatonin induces neuritogenesis at early stages in N1E-115 cells through actin rearrangements via activation of protein kinase C and Rho-associated kinase. J Pineal Res 42: 214-221
114. Moriya, T, Horie, N, Mitome, M, Shinohara, K. 2007. Melatonin influences the proliferative and differentiative activity of neural stem cells. J Pineal Res 42: 411-418
115. Jimenez-Jorge, S, Jimenez-Caliani, AJ, Guerrero, JM, et al. 2005. Melatonin synthesis and melatonin-membrane receptor (MT1) expression during rat thymus development: Role of the pineal gland. J Pineal Res 39: 77-83
116. Sethi, S, Radio, NM, Kotlarczyk, M, et al. 2010. Determination of the minimal melatonin exposure required to induce osteoblast differentitation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res. doi:10.1111/j.1600-079X.2010.00784.x
117. Sethi, S, Radio, NM, Kotlarczyk, M, et al. 2005. Melatonin. Monograph. Altern Med Rev 10: 326-336
118. Jung, B, Ahmad, N. 2006. Melatonin in cancer management: Progress and promise. Cancer Res 66: 9789-9793
119. Sideras, K, Ingle, JN, Ames, MM, et al. 2010. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28: 2768-2776
120. Demuro, RL, Nafziger, AN, Blask, DE, Menhinick, AM, Bertino, JS, Jr. 2000. The absolute bioavailability of oral melatonin. J Clin Pharmacol 40: 781-784
121. Korkmaz, A, Sanchez-Barcelo, EJ, Tan, DX, Reiter, RJ. 2009. Role of melatonin in the epigenetic regulation of breast cancer. Breast Cancer Res Treat 115: 13-27
122. Canaple, L, Kakizawa, T, Laudet, V. 2003. The days and nights of cancer cells. Cancer Res 63: 7545-7552
123. Zhu, Y, Brown, HN, Zhang, Y, Stevens, RG, Zheng, T. 2005. Period3 structural variation: A circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 14: 268-270
124. Chen, ST, Choo, KB, Hou, MF, Yeh, KT, Kuo, SJ, Chang, JG. 2005. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26: 1241-1246
125. Gery, S, Gombart, AF, Yi, WS, Koeffler, C, Hofmann, WK, Koeffler, HP. 2005. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106: 2827-2836
126. Yang, X, Wood, PA, Oh, EY, Du-Quiton, J, Ansell, CM, Hrushesky, WJ. 2009. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat 117: 423-431
127. Yang, X, Wood, PA, Ansell, C, Hrushesky, WJ. 2009. Circadian time-dependent tumor suppressor function of period genes. Integr Cancer Ther 8: 309-316
128. Lissoni, P, Pittalis, S, Ardizzoia, A, et al. 1996. Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin. Support Care Cancer 4: 313-316
129. Lissoni, P, Barni, S, Brivio, F, et al. 1995. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology 52: 360-362
130. Lissoni, P, Tancini, G, Barni, S, et al. 1996. The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia. Recenti Prog Med 87: 582-585
131. Lissoni, P, Paolorossi, F, Tancini, G, et al. 1996. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 32A: 1340-1343
132. Valtonen, M, Niskanen, L, Kangas, AP, Koskinen, T. 2005. Effect of melatonin-rich night-time milk on sleep and activity in elderly institutionalized subjects. Nord J Psychiatry 59: 217-221
133. Gubin, DG, Gubin, GD, Waterhouse, J, Weinert, D. 2006. The circadian body temperature rhythm in the elderly: Effect of single daily melatonin dosing. Chronobiol Int 23: 639-658
134. Norsa, A, Martino, V. 2007. Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. Cancer Biother Radiopharm 22: 50-55